Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Puma Biotechnology, Inc.

NASDAQ: PBYI · Life Sciences · 5 alerts · CIK 1401667

Share price
$7.34Close, Nov 16
Market cap
$379M
Shares outstanding
51.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Puma Biotechnology, Inc. filings on SEC EDGAR ↗

7:36 PM ET Form 4
Insider Selling

Puma Biotechnology Insider Michael Patrick Miller Sells $121K of Stock

Michael Patrick Miller sold 15,000 shares of Puma Biotechnology, Inc. at $8.10 a share, worth $121K in total on Nov 11, 2026. Shares held after the trade: 66,000 (-18.5%).

Value
$121K
Shares
15,000
Price
$8.10
Holding change
-18.5%
Trade date
Nov 11, 2026
4:34 PM ET 10-Q
Financial Results

Puma Biotechnology Q3 2026 Results: Net Income $5.96M, Down 32.7% YoY

Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026, driven primarily by NERLYNX product sales. While the company remained profitable with a net income of $6.0 million, this was a decrease from $8.8 million in the prior year's third quarter due to higher research and development expenses.

Key figure
Net income $5.96M · -32.7% YoY
4:17 PM ET 8-K
Financial Results

Puma Biotechnology Financial Results

Puma Biotechnology reported Q3 2026 financial results with total product revenue of $54.1 million, driven by sales of NERLYNX. The company reported GAAP net income of $6.0 million and raised its full-year 2026 net income guidance while continuing to advance its alisertib clinical development programs.

Term
Q3 2026

“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter.”

Alan H. Auerbach, Chairman, Chief Executive Officer and President

“We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA® clinical development programs.”

Alan H. Auerbach, Chairman, Chief Executive Officer and President
9:14 PM ET Form 4
Insider Selling

Puma Biotechnology Insider Troy Edward Wilson Sells $45.5K of Stock

Troy Edward Wilson sold 5,000 shares of Puma Biotechnology, Inc. at $9.10 a share, worth $45.5K in total on Sep 14, 2026. Shares held after the trade: 54,750 (-8.4%).

Value
$45.5K
Shares
5,000
Price
$9.10
Holding change
-8.4%
Trade date
Sep 14, 2026
9:07 PM ET Form 4
Insider Selling

Puma Biotechnology Insider Alessandra Cesano Sells $567K of Stock

Alessandra Cesano sold 62,150 shares of Puma Biotechnology, Inc. at $9.12 a share, worth $567K in total on Sep 14, 2026. Shares held after the trade: 56,700 (-52.3%).

Value
$567K
Shares
62,150
Price
$9.12
Holding change
-52.3%
Trade date
Sep 14, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.